The ixabepilona is a semi-synthetic analog of the epotilona B it has a directly union of sub unity of β-tubuline in the micro tubules, it mechanism conduce to the cellular death. The results of the clinical studies of ixabepilona were encouraging; the middle age of the patients in these studies was of 52 years old. The breast cancer in young women less than (<40 years) has a physiopathology more aggressive with mayor risk of recurrence and we obtain inferior results. There is little available information about the breast cancer in Latin America; it has been especially difficult for the financial considerations and problems with the access to the health services. In these series of clinical cases and revision let us information about the use of ixabepilona for the treatment of young women with breast cancer in Central America and in the Sur.